Coronary Artery DiseaseNCT07888465
MCG Algorithm Optimization Study in Patients With Coronary Artery Stenosis
An observational study of Coronary Artery Disease, run by AMCG.
Trial summary
This prospective, multicenter study aims to optimize the Magnetocardiography (MCG) algorithm for detecting myocardial ischemia in patients with coronary artery stenosis. Eligible patients will undergo MCG measurements at rest and following treadmill exercise stress testing. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Coronary Artery Disease
- How many people
- 165 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2026to 29 Oct 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with suspected or confirmed coronary artery disease
Who may be able to join
- Adults with suspected or confirmed coronary artery disease.
- Patients able to undergo the required study assessments.
- Patients who voluntarily provide written informed consent.
Who cannot join
- Patients with contraindications to the required study procedures.
- Patients with unstable cardiovascular conditions.
- Patients with medical conditions or prior procedures that may interfere with study assessments.
- Pregnant or breastfeeding women.
- Patients considered unsuitable for participation by the investigator.
About this study
Official title: A Prospective Multicenter Registry Study for the Optimization of Magnetocardiography (MCG) Algorithm in Patients With Moderate-to-Severe Coronary Artery Stenosis (Derivation Phase)
This prospective, multicenter study aims to optimize the Magnetocardiography (MCG) algorithm for detecting myocardial ischemia in patients with coronary artery stenosis.
Eligible patients will undergo MCG measurements at rest and following treadmill exercise stress testing. Adenosine pharmacological stress testing may also be performed at the investigator's discretion.
The results of this study will provide clinical data for improving the diagnostic accuracy of MCG in patients with suspected coronary artery disease.
- Conditions
- Coronary Artery Disease
- Medical subject headings
- Coronary Artery Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic Performance of the MCG-S Algorithm (AUROC)
The diagnostic performance of the MCG-S algorithm will be assessed using the area under the receiver operating characteristic curve (AUROC) against a reference standard.
Measured: Day 1 (In-hospital visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion29 Oct 2027 (estimated)
- Study completion29 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 165 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AMCG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07888465
- Sponsor's protocol ID
- AMCG-CT03
- Status last verified
- Oct 2026
- First submitted
- 14 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Multicenter Registry Study for the Optimization of Magnetocardiography (MCG) Algorithm in Patients With Moderate-to-Severe Coronary Artery Stenosis (Derivation Phase)
- ClinicalTrials.gov ID
- NCT07888465
- Acronym / sponsor ID
- AMCG-CT03
- Conditions
- Coronary Artery Disease
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 165 participants (estimated)
- Lead sponsor
- AMCGIndustry (pharma, biotech, devices)
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 29 Oct 2027 (estimated)
- Study completion
- 29 Oct 2027 (estimated)
- First posted
- 22 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, multicenter study aims to optimize the Magnetocardiography (MCG) algorithm for detecting myocardial ischemia in patients with coronary artery stenosis.
Eligible patients will undergo MCG measurements at rest and following treadmill exercise stress testing. Adenosine pharmacological stress testing may also be performed at the investigator's discretion.
The results of this study will provide clinical data for improving the diagnostic accuracy of MCG in patients with suspected coronary artery disease.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with suspected or confirmed coronary artery disease
Key inclusion criteria (3 listed)
- Adults with suspected or confirmed coronary artery disease.
- Patients able to undergo the required study assessments.
- Patients who voluntarily provide written informed consent.
Key exclusion criteria (5 listed)
- Patients with contraindications to the required study procedures.
- Patients with unstable cardiovascular conditions.
- Patients with medical conditions or prior procedures that may interfere with study assessments.
- Pregnant or breastfeeding women.
- Patients considered unsuitable for participation by the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Diagnostic Performance of the MCG-S Algorithm (AUROC)
Time frame: Day 1 (In-hospital visit)
The diagnostic performance of the MCG-S algorithm will be assessed using the area under the receiver operating characteristic curve (AUROC) against a reference standard.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Recruiting
Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
ST-Elevation Myocardial Infarction (STEMI)
Active, not recruiting
Insulin Resistance and Coronary Microvascular Dysfunction in Patients With Myocardial Ischemia and Non-obstructive Coronary Artery Disease
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Not yet recruiting
TRADENT Scoring Balloon Versus Non-scoring Balloon for Lesion Preparation in DCB-Based Coronary Intervention
Coronary Artery Disease (CAD)
Not yet recruitingObservational study
Prognostic Value of Functional-Nutritional Status in Older Adults With Acute Coronary Syndrome
Acute Coronary Syndromes (ACS)
RecruitingPhase 4
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by AMCG.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnostic Performance of the MCG-S Algorithm (AUROC) (time frame: Day 1 (In-hospital visit)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.